Tag: Cancer: Prostate

Use of NeuroSAFE to guide nerve-sparing surgery results in improvement in erectile function at 12 months and urinary continence at three months

Physician-scored and patient-reported bowel toxicity higher with dose-escalated moderately hypofractionated radiotherapy

Authors say PSA level should be assessed for at least three months after radical prostatectomy for prostate cancer to accurately document persistent PSA

Talazoparib + enzalutamide linked to improved survival for patients with mCRPC unselected for HRR gene alterations

127 patients underwent prostate biopsy, with 94 prostate cancers diagnosed; 86.2 percent had clinically significant disease

Risk for death significantly lower for patients with return of serum testosterone to normal range value

Clinically significant improvement seen in fatigue, and improvement seen in relative peak aerobic capacity with 12-week exercise regimen

Acute genitourinary, GI toxicity linked to late genitourinary or GI toxicity and decrement in urinary or bowel quality of life

MPS2 provides meaningful improvement in detection of grade group ≥2 cancer relative to PSA-based testing approaches

At the same time, incidence of distant-stage prostate cancer increased